CA2849765C - Hybrid constant regions - Google Patents

Hybrid constant regions Download PDF

Info

Publication number
CA2849765C
CA2849765C CA2849765A CA2849765A CA2849765C CA 2849765 C CA2849765 C CA 2849765C CA 2849765 A CA2849765 A CA 2849765A CA 2849765 A CA2849765 A CA 2849765A CA 2849765 C CA2849765 C CA 2849765C
Authority
CA
Canada
Prior art keywords
igg
hybrids
retain
regions
iga
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2849765A
Other languages
English (en)
French (fr)
Other versions
CA2849765A1 (en
Inventor
J. Yun Tso
Naoya Tsurushita
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
JN Biosciences LLC
Original Assignee
JN Biosciences LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by JN Biosciences LLC filed Critical JN Biosciences LLC
Publication of CA2849765A1 publication Critical patent/CA2849765A1/en
Application granted granted Critical
Publication of CA2849765C publication Critical patent/CA2849765C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA2849765A 2011-09-26 2012-09-26 Hybrid constant regions Active CA2849765C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161539416P 2011-09-26 2011-09-26
US61/539,416 2011-09-26
PCT/US2012/057393 WO2013049254A1 (en) 2011-09-26 2012-09-26 Hybrid constant regions

Publications (2)

Publication Number Publication Date
CA2849765A1 CA2849765A1 (en) 2013-04-04
CA2849765C true CA2849765C (en) 2021-10-19

Family

ID=47996377

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2849765A Active CA2849765C (en) 2011-09-26 2012-09-26 Hybrid constant regions

Country Status (6)

Country Link
US (2) US8952134B2 (enExample)
EP (1) EP2760891B1 (enExample)
JP (1) JP6205363B2 (enExample)
CN (1) CN103974977A (enExample)
CA (1) CA2849765C (enExample)
WO (1) WO2013049254A1 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9382319B2 (en) 2011-09-26 2016-07-05 Jn Biosciences Llc Hybrid constant regions
CA2849765C (en) 2011-09-26 2021-10-19 Jn Biosciences Llc Hybrid constant regions
CA2872908C (en) 2012-05-10 2023-11-14 Gerhard Frey Multi-specific monoclonal antibodies
WO2014022592A1 (en) * 2012-08-02 2014-02-06 Jn Biosciences Llc Antibodies or fusion proteins multimerized via cysteine mutation and a mu tailpiece
US20150038682A1 (en) * 2013-08-02 2015-02-05 Jn Biosciences Llc Antibodies or fusion proteins multimerized via homomultimerizing peptide
CA2922830A1 (en) * 2013-09-05 2015-04-16 Igm Biosciences, Inc. Constant chain modified bispecific, penta- and hexavalent ig-m antibodies
TW201619188A (zh) * 2014-03-05 2016-06-01 優稀美生物醫藥公司 多聚體Ｆｃ蛋白質
JP6851199B2 (ja) * 2014-03-05 2021-03-31 ユーシービー バイオファルマ エスアールエル 多量体Ｆｃタンパク質
US10280208B2 (en) 2014-04-30 2019-05-07 Albert Einstein College Of Medicine TMIGD2 and its derivatives as blockers or binders of cancer-expressed HHLA2 for immunotherapies
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
EP3750918A1 (en) * 2015-01-20 2020-12-16 IGM Biosciences, Inc. Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof
JP6882184B2 (ja) * 2015-03-25 2021-06-02 アイジーエム バイオサイエンシズ インコーポレイテッド 多価ｂ型肝炎ウイルス抗原結合分子およびその使用
MX2017012805A (es) * 2015-04-07 2018-04-11 Genentech Inc Complejo de unión a antígenos con actividad agonista y métodos de uso.
WO2016168758A1 (en) 2015-04-17 2016-10-20 Igm Biosciences, Inc. Multi-valent human immunodeficiency virus antigen binding molecules and uses thereof
GB201515745D0 (en) * 2015-09-04 2015-10-21 Ucb Biopharma Sprl Proteins
JP2019511458A (ja) * 2016-01-27 2019-04-25 ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト 組み換えＩｇＧ Ｆｃ多量体
US20190330360A1 (en) * 2016-07-20 2019-10-31 Igm Biosciences, Inc. Multimeric gitr binding molecules and uses thereof
US11401337B2 (en) * 2017-04-07 2022-08-02 Igm Biosciences, Inc. Modified human IgM constant regions for modulation of complement-dependent cytolysis effector function
US11542330B2 (en) * 2017-05-08 2023-01-03 Adimab, Llc Anti-CD3-binding domains and antibodies comprising them, and methods for their generation and use
US20200392239A1 (en) * 2018-02-26 2020-12-17 Igm Biosciences, Inc. Use of a multimeric anti-dr5 binding molecule in combination with a chemotherapeutic agent for treating cancer
US12060419B2 (en) 2018-06-14 2024-08-13 Regeneron Pharmaceuticals, Inc. CD79A chimeric antigen receptors
KR20210009421A (ko) 2018-06-14 2021-01-26 바이오아트라, 엘엘씨 다중 특이적 항체 구조체
KR20210083260A (ko) * 2018-10-23 2021-07-06 아이쥐엠 바이오사이언스 인코포레이티드 다가 IgM- 및 IgA-Fc 기반 결합 분자
CA3115547A1 (en) * 2018-11-14 2020-05-22 Jn Biosciences Llc Multimeric hybrid fc proteins for replacement of ivig
JP7774447B2 (ja) 2019-06-07 2025-11-21 アディマブ・リミテッド・ライアビリティ・カンパニー 高アフィニティ抗ｃｄ３抗体、ならびにその作製方法及び使用方法
EP3983445A4 (en) * 2019-06-14 2023-06-21 2seventy bio, Inc. COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER
EP4130047A4 (en) * 2020-02-27 2024-07-31 Huahui Health Ltd. SOLUBLE ACE2 AND FUSION PROTEIN AND THEIR USES
WO2022080912A1 (ko) * 2020-10-16 2022-04-21 주식회사 아이엠바이오로직스 IgM 영역을 이용한 융합단백질 플랫폼
MX2023015461A (es) * 2021-06-17 2024-01-18 Fapon Biotech Inc Inmunoglobulina quimerica.
KR20240034234A (ko) 2021-07-14 2024-03-13 2세븐티 바이오, 인코포레이티드 항체로부터의 결합 도메인에 융합된 조작된 t 세포 수용체
CN119546327A (zh) 2022-04-08 2025-02-28 再生元制药公司 多部分受体和信号传导复合物
WO2024196707A2 (en) * 2023-03-17 2024-09-26 The Board Of Trustees Of The University Of Illinois Chimeric antibody molecules based on tetrameric teleost immunoglobulin m
EP4606901A1 (en) * 2024-01-02 2025-08-27 Gempharmatech Co., Ltd Animal model for producing humanized antibody, and construction method therefor
KR20250173023A (ko) * 2024-05-30 2025-12-10 주식회사 아이엠바이오로직스 J 사슬에 연결되는 링커 및 이를 포함하는 j 사슬 복합체
CN119638846B (zh) * 2025-01-09 2025-11-04 康复大学青岛中心医院 uMtCK抗体或其抗原结合片段
CN121405821A (zh) * 2025-12-30 2026-01-27 山东大学 一种融合蛋白及在制备治疗或预防乙肝病毒产品中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8719963D0 (en) * 1987-08-24 1987-09-30 Cattaneo A Recombinant dna products
DE10001372A1 (de) * 2000-01-14 2001-08-02 Deutsches Krebsforsch Anti-CD3-Einzelketten-Antikörper mit humanem Cmu3- und Cmu4- Domänen
US7951378B2 (en) * 2000-04-28 2011-05-31 Planet Biotechnology Inc. Immunoadhesin comprising a chimeric ICAM-1 molecule produced in a plant
US7754208B2 (en) * 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
CA2433877C (en) * 2001-01-17 2014-11-18 Aptevo Research And Development Llc Binding domain-immunoglobulin fusion proteins
KR100900176B1 (ko) * 2001-03-07 2009-06-02 메르크 파텐트 게엠베하 하이브리드 이소타입 항체 부분구조를 포함하는 단백질을위한 발현 기술
AU2004289820A1 (en) * 2003-11-13 2005-05-26 Dsm Ip Assets B.V. Use of a vulcanised thermoplastic elastomer or styrene-ethylene-butadiene-styrene polymer as infill material in artificial turf systems
CN101778867A (zh) * 2007-06-08 2010-07-14 地中海大学 用于治疗胰腺肿瘤的组合物和方法
CA2849765C (en) 2011-09-26 2021-10-19 Jn Biosciences Llc Hybrid constant regions

Also Published As

Publication number Publication date
JP2015501291A (ja) 2015-01-15
CN103974977A (zh) 2014-08-06
US20150073130A1 (en) 2015-03-12
EP2760891A1 (en) 2014-08-06
US20130089547A1 (en) 2013-04-11
CA2849765A1 (en) 2013-04-04
EP2760891A4 (en) 2015-06-24
US8952134B2 (en) 2015-02-10
JP6205363B2 (ja) 2017-09-27
EP2760891B1 (en) 2018-11-07
WO2013049254A1 (en) 2013-04-04

Similar Documents

Publication Publication Date Title
CA2849765C (en) Hybrid constant regions
IN2015DN01361A (enExample)
AU2018260863A1 (en) Human IgG1 Fc region variants and uses thereof
MX2013007392A (es) Anticuerpo modificado con vida media mejorada.
WO2016081746A3 (en) Antibodies comprising modified heavy constant regions
NZ628528A (en) Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
SG10201407935YA (en) Humanized anti-il-10 antibodies for the treatment of systemic lupus erythematosus (sle)
UA103499C2 (ru) Антитело против интерлейкина-17 (ил-17) человека и его применение
NZ618067A (en) Anti-cd100 antibodies and methods for using the same
IN2012DN02535A (enExample)
AU2018272852A8 (en) Antibodies comprising modified heavy constant regions
WO2013188693A8 (en) Antigen binding constructs to cd3
NZ602892A (en) Antibodies that bind human cd27 and uses thereof
NZ623319A (en) Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
WO2009128963A3 (en) Cross-neutralizing human monoclonal antibodies to sars-cov and methods of use thereof
MX379533B (es) Ratones de cadena ligera universal humanizados.
EA030777B9 (ru) Анти-альфа-синуклеинсвязывающие молекулы
MX2016015389A (es) Anticuerpos que se enlazan a cd3 epsilon humano y de mono cinomolgo.
EP4417624A3 (en) Antibodies comprising chimeric constant domains
AU2016204274A1 (en) Antibodies that bind to OX40 and their uses
WO2011008517A3 (en) Immunoglobulin fc polypeptides
AU2012307816A8 (en) Anti-alphabeta TCR antibody
WO2010017103A3 (en) Fully human anti-human nkg2d monoclonal antibodies
MX2016006301A (es) Construcciones de unión a antígeno monovalente que se dirigen a egfr y/o her2, y sus usos.
NZ604007A (en) Monoclonal antibodies against her2 epitope

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20170623

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 12TH ANNIV.) - STANDARD

Year of fee payment: 12

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240903

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240903